WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584944
CAS#: 68548-99-2
Description: Oxindanac is a nonsteroidal anti-inflammatory drug.
MedKoo Cat#: 584944
Name: Oxindanac
CAS#: 68548-99-2
Chemical Formula: C17H14O4
Exact Mass: 282.0892
Molecular Weight: 282.295
Elemental Analysis: C, 72.33; H, 5.00; O, 22.67
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxindanac, Oxindanaco, Oxindanacum
IUPAC/Chemical Name: (+-)-5-Benzoyl-6-hydroxy-1-indancarboxylic acid
InChi Key: XMTKXTUIUKKGIL-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H14O4/c18-15-9-13-11(6-7-12(13)17(20)21)8-14(15)16(19)10-4-2-1-3-5-10/h1-5,8-9,12,18H,6-7H2,(H,20,21)
SMILES Code: O=C(C1CCC2=C1C=C(O)C(C(C3=CC=CC=C3)=O)=C2)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 282.295 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: King JN. The use of intradermal carrageenan in calves to estimate the dose of oxindanac, a nonsteroidal anti-inflammatory drug. Can J Vet Res. 1993 Oct;57(4):215-22. PubMed PMID: 8269358; PubMed Central PMCID: PMC1263631.
2: Tamm C, Favre L, Spence S, Pfister S, Vallotton MB. Interaction of oxindanac and frusemide in man. Eur J Clin Pharmacol. 1989;37(1):17-21. PubMed PMID: 2687006.
3: King JN. Correlation between the pharmacokinetics of oxindanac and inhibition of serum thromboxane B2 in calves. J Vet Pharmacol Ther. 1994 Jun;17(3):193-201. PubMed PMID: 7933057.
4: King JN, Mauron C, Voirol MJ, Le Goff C, Hauffe SA. High performance liquid chromatography and pharmacokinetics of the non-steroidal anti-inflammatory drug oxindanac in calves. J Vet Pharmacol Ther. 1994 Jun;17(3):186-92. PubMed PMID: 7933056.
5: Gross W, Sinterhauf U, Gross S, Kluger H. The influence of Oxindanac on kallikrein metabolism. Adv Exp Med Biol. 1989;247A:393-7. PubMed PMID: 2603808.
6: King JN, Mauron C, LeGoff C, Hauffe S. Bidirectional chiral inversion of the enantiomers of the nonsteroidal antiinflammatory drug oxindanac in dogs. Chirality. 1994;6(6):460-6. PubMed PMID: 7946973.
7: Skoglund LA, Eidsaunet W, Pettersen N. The anti-oedematous efficacy of oxindanac equals that of paracetamol in acute postoperative inflammation; are weak cyclooxygenase inhibitors more effective than strong inhibitors? Int J Clin Pharmacol Res. 1989;9(6):371-5. PubMed PMID: 2517495.
8: Aabakken L, Dybdahl JH, Eidsaunet W, Haaland A, Larsen S, Osnes M. Optimal assessment of gastrointestinal side effects induced by non-steroidal anti-inflammatory drugs. Endoscopic lesions, faecal blood loss, and symptoms not necessarily correlated, as observed after naproxen and oxindanac in healthy volunteers. Scand J Gastroenterol. 1989 Oct;24(8):1007-13. PubMed PMID: 2688064.
9: Sallmann AR. The history of diclofenac. Am J Med. 1986 Apr 28;80(4B):29-33. PubMed PMID: 3085489.
10: Kadurugamuwa JL, Hengstler B, Zak O. Cerebrospinal fluid protein profile in experimental pneumococcal meningitis and its alteration by ampicillin and anti-inflammatory agents. J Infect Dis. 1989 Jan;159(1):26-34. PubMed PMID: 2462602.
11: Tuomanen E. Modulation of inflammation in bacterial meningitis. Isr J Med Sci. 1994 May-Jun;30(5-6):339-41. Review. PubMed PMID: 8034477.
12: Francotte E, Stierlin H, Faigle JW. Isolation and stereospecific determination of the enantiomers of oxindazac by direct liquid chromatographic resolution on triacetylcellulose. J Chromatogr. 1985 Oct 18;346:321-31. PubMed PMID: 3910671.
13: Aabakken L, Axelsson CK, Szecsi PB. Pepsinogen A and C serum levels in relation to acute NSAID-associated mucosal lesions in healthy volunteers. Scand J Gastroenterol. 1993 Jun;28(6):557-60. PubMed PMID: 8322031.
14: Degen PH, Schneider W. Simultaneous derivatisation of carboxyl and hydroxyl groups of a new antiphlogistic drug for its determination by electron-capture gas chromatography. J Chromatogr. 1983 Oct 14;277:361-7. PubMed PMID: 6643622.
15: Tuomanen E, Hengstler B, Rich R, Bray MA, Zak O, Tomasz A. Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis. J Infect Dis. 1987 May;155(5):985-90. PubMed PMID: 3470394.
